EMI-137

Drug Overview

Fluorescence imaging agent EMI-137 is a highly specialized diagnostic tool used to help surgeons see cancer more clearly during medical procedures. It is not a medicine used to treat or cure a disease. Instead, it is a “Targeted Imaging Agent” that acts like a highlighter for cancer cells. Surgeons use it along with special cameras that detect near-infrared light to find hidden tumors that might be missed by the human eye.

Here are the key details about this agent:

• Generic Name: EMI-137.
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Fluorescence Imaging Agent / Targeted Diagnostic Tracer / c-Met Binding Peptide.
• Route of Administration: Intravenous (IV) injection.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is being studied in advanced clinical trials for various types of cancer.

What Is It and How Does It Work? (Mechanism of Action)

To understand EMI-137, it helps to imagine a dark room where you are looking for a specific object. EMI-137 acts like a glow-in-the-dark sticker that only sticks to that one object. In the body, that “object” is a specific protein found on the surface of many cancer cells.

Targeting the “Lock” (c-Met Receptor)

At the molecular level, EMI 137 is a small protein chain (a peptide) that is designed to fit perfectly into a “lock” called the c-Met receptor. This receptor is a protein that sits on the outside of cells. While healthy cells have very few of these receptors, many types of cancer cells have thousands of them. This makes the c-Met receptor a perfect target for finding cancer.

The Fluorescent “Beacon”

Attached to this peptide is a special dye molecule. This dye is “fluorescent,” meaning that when a specific type of light shines on it, the molecule glows. Here is the step-by-step process of how it works during surgery:

1. Injection and Travel: After EMI-137 is injected into the patient’s blood, it travels throughout the body.
2. Binding: The peptide part of the drug finds the c-Met receptors on cancer cells and locks onto them.
3. Clearance: The drug that does not find a cancer cell is naturally washed out of the body by the kidneys.
4. Imaging: During surgery, the doctor shines a near-infrared light on the area. The EMI-137 that is “locked” onto the cancer cells absorbs this light and glows brightly.
5. Precision Surgery: The surgeon looks at a monitor that shows this glow. This helps them see exactly where the cancer starts and ends, allowing them to remove the tumor more accurately while leaving healthy tissue behind.

FDA-Approved Clinical Indications

Because EMI 137 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Colorectal Cancer: Used during colonoscopies and surgeries to identify polyps and cancerous lesions in the colon.
• Pancreatic Cancer: Used to help surgeons see the edges of tumors in the pancreas, which is traditionally very difficult to operate on.
• Esophageal Cancer: Used to identify early-stage cancer cells in the lining of the esophagus.
• Solid Tumors: Being studied for any tumor that has high levels of the c-Met receptor.

Non-oncological Uses:

• Detection of Inflammation: Some research is looking at whether the drug can help identify severe inflammation in the digestive tract, though this is not the primary focus.

Dosage and Administration Protocols

Because this is a diagnostic agent used for a specific procedure, it is usually given as a single dose shortly before the imaging takes place.

Note: Because the drug is cleared by the kidneys, doctors monitor patients with severe kidney issues closely, though the dose used for imaging is very small.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have shown that EMI 137 is a very effective “Smart Tool” for cancer detection.

• Improved Detection Rates: In trials for colorectal cancer, EMI 137 helped doctors find up to 20% more small or flat polyps that were invisible during a standard colonoscopy.
• Clearer Margins: In pancreatic surgery trials, the use of EMI 137 allowed surgeons to achieve “clear margins” (removing all visible cancer) in a higher percentage of patients compared to surgery without the imaging agent.
• Real-Time Results: Unlike a biopsy which can take days to get results, EMI 137 provides “molecular snapshots” instantly during the procedure. This allows doctors to make immediate decisions while the patient is still in surgery.
• High Sensitivity: Research data shows that the drug has a high “signal-to-background” ratio. This means the cancer glows very brightly while the healthy tissue stays dark, making it very easy for doctors to tell them apart.

Safety Profile and Side Effects

Because EMI 137 is used in very small amounts and is not a toxic chemotherapy drug, it is generally very safe. The dye used is similar to other dyes that have been used in medicine for many years.

Common Side Effects (>10%):

• Injection Site Reactions: Mild redness or a cool feeling in the arm where the IV was placed.
• Nausea: A small number of patients report a slight “upset stomach” shortly after the injection.

Serious Adverse Events:

• Allergic Reactions (Rare): As with any injected substance, there is a very small risk of an allergic reaction (anaphylaxis). This can cause hives, itching, or trouble breathing.
• Kidney Stress (Rare): In patients with already very weak kidneys, there is a small risk of stress as the body clears the dye.

Black Box Warning:

• There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Observation: Patients are usually monitored by a nurse for 30 minutes after the injection to watch for any signs of an allergic reaction.
• Hydration: Patients are encouraged to drink extra water after their procedure to help the kidneys wash the agent out of their system quickly.
• Emergency Meds: The medical team always has allergy medications (like antihistamines) ready just in case a reaction happens.

Research Areas

While EMI-137 is primarily a diagnostic tool, it is also being looked at in Research Areas related to “Theranostics.” This is a new field where the same “Targeted” platform used for imaging can be used to deliver medicine.

Scientists are researching whether they can replace the fluorescent dye on the EMI-137 peptide with a small amount of radiation or chemotherapy. This would allow the drug to not only “find” the c-Met receptor but also kill the cancer cell once it arrives. There is also interest in using EMI-137 to monitor how well Immunotherapy is working; if a tumor stops “glowing” over time, it could be a sign that the treatment is successfully killing the cancer cells.

Patient Management and Practical Recommendations

To get the best results from an EMI-137 scan or surgery, patients should follow these guidelines.

Pre-treatment Tests to be Performed:

• Kidney Function Test: A simple blood test (Creatinine/GFR) to make sure your kidneys are healthy enough to clear the dye.
• Allergy History: Your doctor will ask if you have ever had a reaction to medical dyes or “contrast agents” used in X-rays or CT scans.

Precautions During Treatment:

• Lighting: The imaging is done using special near-infrared light. You will not feel this light, and it is safe for your skin and eyes.
• Movement: If the drug is being used during a colonoscopy, you must follow the standard “prep” instructions so the doctor has a clear view of the colon walls.

“Do’s and Don’ts” List:

• DO tell your doctor if you are pregnant or breastfeeding, as the effects of the dye on babies are not yet fully known.
• DO drink plenty of water after your procedure.
• DON’T worry if your urine looks slightly different in color for 24 hours; this is just the dye leaving your body.
• DON’T skip your follow-up appointment to discuss the findings of the imaging.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Fluorescence imaging agent EMI-137 is an investigational diagnostic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, medical procedures, and eligibility for clinical trials.